This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Antigenics Vaccine Booster Baked Into Valuation: BioBuzz

LEXINGTON, Mass. ( TheStreet) -- I spent a very long day at the Rodman & Renshaw investor conference Wednesday (Amtrak's Acela between Boston and New York City is a nice way to travel, but roundtrip in a single day? Arduous).

I'll have updates and news from my Rodman conference trip over the next several days, but let's get started with Antigenics (AGEN - Get Report). The company's royalty rate for its experimental vaccine adjuvant QS21 ranges from 1.5% to 6% depending on the vaccine, but is generally in the low single digits, said CFO Shalini Sharp in a response to my question after her presentation.

I'm glad she answered the question because the company hasn't been willing in the past to shed much light on the QS21 royalty rate agreements it has with various partners who are developing vaccines containing the Antigenics' adjuvant as a booster.

The not-so-good news for Antigenics is that a low single-digit royalty rate doesn't bring in that much money, especially compared to the company's current valuation.

For example, let's assume that GlaxoSmithKline's (GSK - Get Report) malaria vaccine (which contains QS21) is launched in 2011 and peaks at $1 billion in sales by the end of 2014. I'm going to also assume Antigenics' royalty rate at 1.5% (likely since a malaria vaccine is a low-margin product sold primarily in the undeveloped world.)

That works out to $15 million in royalty revenue for Antigenics. But of course, that's five years in the future, so the net present value of that revenue today is just over $7 million. At a multiple of six times, that's worth just under $43 million in current enterprise value, or 48 cents a share, for Antigenics.
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AMAG $27.43 3.00%
AGEN $5.14 0.59%
GSK $40.88 0.91%
AAPL $117.15 -0.97%
FB $106.95 2.60%


Chart of I:DJI
DOW 17,852.18 +132.26 0.75%
S&P 500 2,096.63 +16.22 0.78%
NASDAQ 5,145.8940 +37.2280 0.73%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs